These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30887764)

  • 1. Combined estrogen-progestin pill is a safe and effective option for endometrial hyperplasia without atypia: a three-year single center experience.
    Wang Y; Nisenblat V; Tao L; Zhang X; Li H; Ma C
    J Gynecol Oncol; 2019 May; 30(3):e49. PubMed ID: 30887764
    [TBL] [Abstract][Full Text] [Related]  

  • 2. National patterns of care and fertility outcomes for reproductive-aged women with endometrial cancer or atypical hyperplasia.
    Harrison RF; He W; Fu S; Zhao H; Sun CC; Suidan RS; Woodard TL; Rauh-Hain JA; Westin SN; Giordano SH; Meyer LA
    Am J Obstet Gynecol; 2019 Nov; 221(5):474.e1-474.e11. PubMed ID: 31128110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis.
    Chae-Kim J; Garg G; Gavrilova-Jordan L; Blake LE; Kim TT; Wu Q; Hayslip CC
    Int J Gynecol Cancer; 2021 Dec; 31(12):1499-1505. PubMed ID: 34785524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic factors of oncological and reproductive outcomes in fertility-sparing treatment of complex atypical hyperplasia and low-grade endometrial cancer using oral progestin in Chinese patients.
    Zhou R; Yang Y; Lu Q; Wang J; Miao Y; Wang S; Wang Z; Zhao C; Wei L
    Gynecol Oncol; 2015 Dec; 139(3):424-8. PubMed ID: 26428941
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial.
    JAMA; 1996 Feb; 275(5):370-5. PubMed ID: 8569016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Pregnant rate and pregnancy-relating factors of patients with early endometrial carcinoma and severe atypical hyperplasia of endometrium after fertility-preserving treatment by progestin].
    Cao DY; Yu M; Yang JX; Shen K; Huang HF; Cheng NH; Sun ZY; Deng CY; Yu Q; He FF
    Zhonghua Fu Chan Ke Za Zhi; 2013 Jul; 48(7):519-22. PubMed ID: 24284224
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Should progesterone and estrogen receptors be assessed for predicting the response to conservative treatment of endometrial hyperplasia and cancer? A systematic review and meta-analysis.
    Raffone A; Travaglino A; Saccone G; Mollo A; De Placido G; Insabato L; Zullo F
    Acta Obstet Gynecol Scand; 2019 Aug; 98(8):976-987. PubMed ID: 30779338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LNG-IUS versus oral progestogen treatment for endometrial hyperplasia: a long-term comparative cohort study.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 Nov; 28(11):2966-71. PubMed ID: 23975691
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials.
    Abu Hashim H; Ghayaty E; El Rakhawy M
    Am J Obstet Gynecol; 2015 Oct; 213(4):469-78. PubMed ID: 25797236
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Progestin therapy for obese women with complex atypical hyperplasia: levonorgestrel-releasing intrauterine device vs systemic therapy.
    Mandelbaum RS; Ciccone MA; Nusbaum DJ; Khoshchehreh M; Purswani H; Morocco EB; Smith MB; Matsuzaki S; Dancz CE; Ozel B; Roman LD; Paulson RJ; Matsuo K
    Am J Obstet Gynecol; 2020 Jul; 223(1):103.e1-103.e13. PubMed ID: 31978437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Progestin plus metformin improves outcomes in patients with endometrial hyperplasia and early endometrial cancer more than progestin alone: a meta-analysis.
    Shao F; Li Y; Zhao Y
    Front Endocrinol (Lausanne); 2023; 14():1139858. PubMed ID: 37415671
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oncologic and reproductive outcomes after fertility-sparing management with oral progestin for women with complex endometrial hyperplasia and endometrial cancer.
    Chen M; Jin Y; Li Y; Bi Y; Shan Y; Pan L
    Int J Gynaecol Obstet; 2016 Jan; 132(1):34-8. PubMed ID: 26493012
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer.
    Yang B; Xu Y; Zhu Q; Xie L; Shan W; Ning C; Xie B; Shi Y; Luo X; Zhang H; Chen X
    Gynecol Oncol; 2019 Apr; 153(1):55-62. PubMed ID: 30674421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progestin-only pills for contraception.
    Grimes DA; Lopez LM; O'Brien PA; Raymond EG
    Cochrane Database Syst Rev; 2010 Jan; (1):CD007541. PubMed ID: 20091638
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of pretreatment with oral contraceptives and progestins on IVF outcomes in women with polycystic ovary syndrome.
    Wei D; Shi Y; Li J; Wang Z; Zhang L; Sun Y; Zhou H; Xu Y; Wu C; Liu L; Wu Q; Zhuang L; Du Y; Li W; Zhang H; Legro RS; Chen ZJ
    Hum Reprod; 2017 Feb; 32(2):354-361. PubMed ID: 27999118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of pathological assessment of endometrial tissue in fertility-sparing treatment with progestin for endometrial carcinoma of stage I a and complex atypical hyperplasia].
    Gong Q; Chen X; Xie X
    Zhonghua Fu Chan Ke Za Zhi; 2014 Sep; 49(9):664-9. PubMed ID: 25487452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral contraceptive pill, progestogen or estrogen pre-treatment for ovarian stimulation protocols for women undergoing assisted reproductive techniques.
    Smulders B; van Oirschot SM; Farquhar C; Rombauts L; Kremer JA
    Cochrane Database Syst Rev; 2010 Jan; (1):CD006109. PubMed ID: 20091585
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estrogen-progestin replacement therapy and endometrial cancer.
    Pike MC; Peters RK; Cozen W; Probst-Hensch NM; Felix JC; Wan PC; Mack TM
    J Natl Cancer Inst; 1997 Aug; 89(15):1110-6. PubMed ID: 9262248
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relapse of endometrial hyperplasia after conservative treatment: a cohort study with long-term follow-up.
    Gallos ID; Krishan P; Shehmar M; Ganesan R; Gupta JK
    Hum Reprod; 2013 May; 28(5):1231-6. PubMed ID: 23466671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complex hyperplasia with and without atypia: clinical outcomes and implications of progestin therapy.
    Reed SD; Newton KM; Garcia RL; Allison KH; Voigt LF; Jordan CD; Epplein M; Swisher E; Upson K; Ehrlich KJ; Weiss NS
    Obstet Gynecol; 2010 Aug; 116(2 Pt 1):365-373. PubMed ID: 20664397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.